Paris, 31 october 2025 – Substipharm announces the acquisition of two well-known pharmaceutical brands: Aspégic®, acquired from Opella, and Kardégic® / Cardirene®, acquired from Sanofi. Both brands have been trusted by healthcare professionals and patients for decades in the fields of pain relief, inflammation, fever management, and cardiovascular prevention.
A strategic transaction combining heritage and continuity
Aspégic® is available in packs of 100 mg, 500 mg, and 1000 mg in France, Benelux, Switzerland. The 250 mg presentation is additionally available in France.
Kardégic® / Cardirene® is available in packs of 75 mg, 160 mg, and 300 mg in France, Italy, and Morocco; Cardirene® 100 mg is additionally available in Italy.
Aspégic® is indicated for the treatment of pain, fever, and inflammation (analgesic, antipyretic, anti-inflammatory).
Kardégic® / Cardirene® is indicated for the prevention of cardiovascular events (antiplatelet therapy to reduce the risk of blood clots, heart attacks, and strokes).
Statement from Léopold Berthier, President of Substipharm:
“Aspégic and Kardégic / Cardirene are familiar names to millions of patients and healthcare professionals. We are proud to ensure their continuity within Substipharm and to strengthen our commitment to delivering trusted medicines to patients.”
About Substipharm
Substipharm is an independent biopharmaceutical company founded 30 years ago in Paris, specializing in the development and commercialization of generics, branded medicines and vaccines. Selling in more than one hundred countries, Substipharm is committed to providing affordable care everywhere.
Press contact:
Raphaëlle Tisserand-Quéré
Email: rtisserand@substipharm.com
Website: www.substipharm.com
